NORTH CHICAGO, Ill., July 9, 2020 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License ...

-- BOTOX® has demonstrated efficacy and has an established safety profile with over 10 years of clinical use in adult upper limb spasticity NORTH CHICAGO, Ill., July 29, 2021 /PRNewswire/ -- Allergan, ...

Botox (onabotulinumtoxinA) is a prescription injection used to treat certain medical conditions by relaxing specific muscles and glands. It comes as a powder that a healthcare professional will mix ...

The US Food and Drug Administration (FDA) has approved onabotulinumtoxinA (Botox, Allergan) to ease upper limb spasticity in children and adolescents aged 2 to 17 years, the company announced. Common ...

Spasticity is a condition that causes muscle stiffness and affects a person’s ability to speak and move. A variety of different treatment options are available to help manage this condition.

Allergan announced that the Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Applications (sBLAs) for Botox (onabotulinumtoxinA) injection for the ...

The FDA has approved Botox for the treatment of lower limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy. The treatment was already approved for ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a label expansion for Botox to include eight new muscles and the use of ultrasound for the ...

Phase IV head-to-head, double-blind trial comparing safety and efficacy met its primary and secondary endpoints The DIRECTION trial results show the safety profile for Dysport® (abobotulinumtoxinA) ...

Botox (onabotulinumtoxinA) is a brand-name drug that’s prescribed for various conditions, including overactive bladder and excessive sweating, in adults and some children. Botox comes as an injection ...